Abbott India Watchlist
Pick of the Week: Abbott India Ltd
129 Views, 11 Jan 2022 17:07
- Revenue growth of Abbott India Ltd (AIL) for FY21 has outpaced the Indian Pharma Market (IPM) growth by 100 bps majorily contributed by addition of new products
- AIL has leadership position in 9 top brands out of 10 in their respective therapies
- We recommend BUY with a TP of Rs 20,000/share.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.